NCT07058025View on ClinicalTrials.gov

Mesenchymal Stromal Cell Therapy to Prevent Bronchopulmonary Dysplasia in Extreme Preterm Infants

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

168

Participants

Timeline

Start Date

October 1, 2025

Primary Completion Date

September 30, 2028

Study Completion Date

September 30, 2038

Conditions
Bronchopulmonary Dysplasia (BPD)ELGAN (22-28SA)
Interventions
BIOLOGICAL

Human Allogenic Umbilical Cord Mesenchymal Stromal Cells

IV administration of uc-MSC every 7 days ± 1 day for 3 weeks. Randomized double blinded

OTHER

Sham procedure control

Sham procedure (mimic IV catheter insertion adn cell product infusion behing a screen). Repeated weekly for 3 weeks

Trial Locations (8)

T5H 3V9

Royal Alexandra Hospital/Stollery Children's Hospital, Edmonton

L8Z 3Z5

McMaster Children's Hospital, Hamilton

K1H 8L6

The Ottawa Hospital, Ottawa

M4Y 3M5

Sunnybrook Health Sciences Ctr, Toronto

M5G 1X5

Mount Sinai Hospital, Toronto

H3T 1C5

CHU Sainte-Justine, Montreal

H4A 3J1

McGill Montreal Children's Hospital, Montreal

G1V 0B4

Université Laval, Québec

Sponsors
All Listed Sponsors
collaborator

Canadian Institutes of Health Research (CIHR)

OTHER_GOV

collaborator

Stem Cell Network

OTHER

lead

Ottawa Hospital Research Institute

OTHER